You are here

GATC Health

Overview
Updates (29)
Comments
Contact
 

GATC Health is transforming how we diagnose and treat disease.

Imagine knowing your precise risk for Alzheimer's—or your child's risk of diabetes, decades before a potential diagnosis.

Imagine addiction cured once and for all.

Imaginelife-saving drugs developed in months, not years.

With GATC Health's AI-powered research, imagination becomes reality.

250 savvy investors have invested $15 million in the future of medicine: GATC Health.

You can too.

→ Offering Completed

 

GATC Health - A Game Changer In The Drug Development Sector

Human DNA holds the secrets to ending disease like addiction and PTSD. GATC Health is unlocking those secrets with our proprietary biotech.

Most recently, our AI-powered research has developed promising new pre-clinical molecules for PTSD, fentanyl addiction, and cocaine addiction...in mere months, not years.

The next step? In-vitro and pre-clinical testing.

→ Offering Completed

  • Discovering The Shortest Path to Better Drugs
    We believe GATC Health’s advanced AI platform creates
    safer, more effective therapeutics
    in record time.

    Offering Completed

  • GATC Health works to accelerate, optimize and
    de-risk drug discovery and development—creating
    tremendous value for our partners and customers.
    Our advanced technology closes the “AI Gap,”
    potentially saving years of R&D time and hundreds
    of millions of dollars per project.

    Offering Completed

 
Download Our Investment Presentation

What makes this technology different?

 

GATC Health’s proprietary AI simulates individual human biology to:

  • Discover new drugs or repurpose existing drugs in record time
  • De-risk drug development and clinical trials
  • Assess individual health risks
  • Recommend the best treatment options

These breakthroughs are possible with GATC Health’s patented platform, which functionally acts like a digital humanoid. Drawing on large sets of public and proprietary multiomic data, our AI simulates human biology’s billions of interactions which, we believe, leads to the following: (i) rapid and accurate target discovery, (ii) drug identification, (iii) development and (iv) validation of safety and efficacy.

At the core of our work are two proprietary assets:

Our company’s patented AI, Multiomics Advanced Technology™, or MAT.

In our opinion, MAT is unlike any other health tech AI. It is a purpose-built combination of artificial intelligence, deep machine learning and neural networks. It mimics human biology to understand diseases and treatments faster and more accurately.

An ultra-valuable multiomics biological dataset.

Genetics (DNA) provide a blueprint for what will become a human. But a 50-year-old human may differ from its “blueprint” just as a 50-year-old building differs from its original plan. Multiomics is the study of ALL the molecules in the human body involved with biological processes, including transcriptomics, proteomics, enviromics, metabolomics1. They help us understand what happens to a human over time, taking into account lifestyle, diet and environmental factors. GATC is accumulating a valuable multiomics dataset through direct data-gathering, public sources and partnerships. This multiomics dataset enables our team of leading scientists to achieve advancements in disease detection and drug discovery.

→ Offering Completed

Our Team

GATC Health is led by world-class scientists and seasoned finance professionals with over $12 billion combined funding. Prior to building GATC’s MAT platform, the firm’s experts developed some of the world’s best-known web-based technologies.

GATC Health’s leadership team intends to deliver value to shareholders and a clear path to an exit event.

Providing expert guidance to GATC’s management is the company’s Board of Advisors, which includes top researchers, medical doctors, employee benefits experts, biotech executives and government contracting experts.

 
image
John Stroh
Interim Chief Executive Officer

› 30+ years as an investment banker specializing in the health care sector

› CEO, Global Healthcare Advisors

› President & CEO, Nanospectra Biosciences

› COO, CFO & SVP, Kadmus Pharmaceuticals

› President, CEO & Director, Neomatrix LLC

 
image
Ian Jenkins
Chief Science Officer, Cofounder

› Developer of the science and process of GATC’s Predictive Multiomics™

› Co-creator of technology for Multiomics Advanced Technologies™

› Former researcher with the Human Genome Project

› VP Clinical Development, ORN Industries

 
image
Jayson Uffens
Chief Technology Officer, Cofounder

› VP Engineering, GrubHub

› Head of Engineering, Seamless

› Engineering Manager & Architect, Northrop Grumman Info Systems

› Senior Engineering Manager, GoDaddy.com

› Lead Application Architect, American Express

 
image
Preetaman Wadhwa
Chief Marketing Officer

› Global Market Lead, Oncology, Amgen

› Marketing Director, Cardiology, Amgen

› Masters Health Systems Management, Rush University

 
image
Eric Mathur
Chief Innovation Officer

› Founder of Stratagene (enabling PCR testing)

› Executive at Diversa Corp, largest biotech IPO at the time

› Recruited by Synthetic Genomics, lead researcher, purchased by Monsanto

› 50+ peer-reviewed publications and 100+ patents

 
image
Tyrone Lam
Chief Operating Officer

› Cofounder, COO, First Americans Health & Wellness

› Cofounder, COO, OneRecovery/OneHealth Solutions

› President, COO, NTN Buzztime

› VP Business Development, Predilytics

 
image
Dr. Jonathan Lakey
Chair of Scientific Advisory Board

› Professor Emeritus, Surgery and Biomedical Engineering, University of California, Irvine

› Co-inventor of the “Edmonton Protocol” islet transplantation surgery for diabetes

› 500+ authored scientific papers

› International speaker

 
image
Jeff Moses
President

› Co-founder, CMO, director of PowerOne Energy Corp

› Multiple C-level positions with growth stage companies

› Founder & creative director of ad agency serving Fortune 500 clients

 
image
Kevin Woodbridge
Executive VP

› 30+ years in finance and corporate development

› Lead $100M+ financing for various companies

 
image
Michael Manahan
Interim Chief Financial Officer

› Professor Cal State University, Dominguez Hills, Entrepreneurial Finance

› President, Match Vest Capital

› Chief Financial Officer, BluTango Inc.

 
image
Chad Penry
Director of Business Development

› Founder, Quan Financial - business consulting & strategic partnerships

› Strategic partnerships with Fortune 500 companies, leading industry professionals, celebrities, artists, athletes, and non-profit organizations.

 

GATC Health: the Future of Drug Development & Precision Medicine

Pharmaceutical R&D: Bridging the AI Gap for Drug Discovery

To our knowledge, GATC Health is the first company to bridge the AI Gap. But what is the AI Gap?

Traditionally, drug companies make assumptions about a disease and possible drug candidate molecules. This creates a giant haystack of data. They spend hundreds of millions of research dollars—and many years—analyzing each strand of “hay” trying to find the needle, or exact drug candidate.

Our competitors use AI to reduce the size of the haystack. At their best, they can reduce the haystack from 10,000 or more possible targets down to approximately 1,000. This can save several years and considerable expense—but it is only an enhancement to the traditional model.

The AI Gap is the difference between what our competitors deliver—a smaller haystack—and what GATC Health’s patented platform can deliver: the exact needle.

GATC Health skips the haystack and creates the needle.
 
 

Personalized Medicine: Genetics-Based Diagnostic Tools for Consumers

Creating new drugs starts with gathering data. Instead of paying for valuable biological data, GATC Health created a model for early disease detection and treatment optimization where customers pay us to collect their data. In turn, GATC provides a personalized, actionable report illustrating disease risk and recommended treatment options.

With a single cheek swab, our proprietary DNA test kits can identify your precise risks and recommended treatment for

  • Viral Immunity
  • Depression & Anxiety
  • Medical Cannabis
  • Health & Wellness

 

The company intends to complete the following diagnostic tools over the next 12 months:

  • Diabetes
  • Cardiac Health
  • Alzheimer’s
  • Parkinson’s
  • PTSD

 

GATC Health licenses these proprietary multiomic diagnostic tests to companies that distribute the products to consumers and physicians, enabling precision and predictive medicine across clinical settings.

New Drug Candidates in Months, Not Years

Via our relationship with Liquid Biosciences, world-class biomarker discovery company, GATC technology has created a new drug discovery platform. In our first project with Liquid Biosciences, GATC has:

  • Validated biomarkers for addiction
  • Discovered a new molecule for addiction treatment
  • We completed this work in a record breaking 9 months
  • Internal estimates of 50% or more reduction in drug discovery timeline
  • Net present value increase of over $500 million per drug, due to risk reduction, cost reduction and acceleration
  • Co-developed an AI-driven pipeline for new drug discovery, which has already produced multiple breakthrough molecules

Liquid Biosciences has completed over 192 projects with major pharmaceutical firms and research organizations for biomarker discovery, diagnostics, drug discovery, drug repurposing, database services, and analytics

 
→ Offering Completed
 
What we do

Who Benefits from GATC Health’s Technology?

In short: everyone.
Pharmaceutical companies: Our tech enables faster and more accurate drug discovery, drug repurposing and drug development. We de-risk and improve value through pre-clinical in silico and in vivo testing, prescreening clinical trial participants and validating clinical trial data.
Individuals: Patients can now access fast and affordable personalized DNA analysis of disease risk, tolerance, complications, and prevention through our distribution partners. Drugs discovered by GATC Health will be safer and more effective because they are better targeted to each disease.
Doctors: With individualized multiomic data for their patients, clinicians can provide cutting-edge, ultra-efficient medical care for better health outcomes.
→ Offering Completed

 

GATC Health Offering

Type:
Reg A + offering
 

 

→ Offering Completed

 

Mark Cuban, one of the most innovative and respected Internet-based entrepreneurs of our time, recently stated that artificial intelligence, “…will have a bigger impact on us than the Internet, than phones, mobile computing, mobile networking, wide-area networking—it’s just going to dwarf everything.” He went on to point out that, “…it’s harder to learn, harder to implement, and not everyone is going to be able to adapt…we are still in the first innings of the preseason game.”

As one of the richest people in the world, Bill Gates is known for contributing to global health through the Gates Foundation. As his biggest legacy, Microsoft is also moving in the same direction. The company is actively involved in helping the world’s population overcome some of the most challenging health problems and concerns.

Microsoft recently announced a new healthcare initiative known as “AI for Health,” a program worth over 40 million dollars. AI for Health evolved out of the AI for Good Program, which offers general aid to the less fortunate around the world.

 
The Market Opportunity

GATC Health sits at the center of four growing markets: genetic testing, AI in healthcare, personalized medicine and the world longevity economy.

Genetic Testing: $28.58 billion by 2026
Artificial Intelligence in Healthcare: $120 billion by 2028
Personalized & Precision Medicine: $493 billion and growing
World Longevity Economy: $27 Trillion in the next 5 years
Offering Completed

Press

GATC Health in the News

image
GATC Health Enters Oncology Drug Market with "Prodrugs for Cancer Treatment" Patent Application

“GATC Health, a biotech company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, today announced it has filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for cancer treatment. This breakthrough, produced by the company's revolutionary Multiomics Advanced Technology™ AI platform, signals GATC Health's entrance into the oncology drug discovery market.”

-PRNewswire, April 2022
image
Artificial Intelligence That “thinks” Like Human Biology Advances Disease Detection, Treatment and Prevention

“Compared to traditional platforms that utilize artificial intelligence to accelerate mathematical, algorithmic models, GATC’S Multiomics Advanced Technology is at the forefront of a new model, where data is given biological context and value. With this distinct advantage, GATC Health provides exponentially faster, easier and more accurate results with far greater accuracy for disease detection, treatment, and therapeutics development.”

-Healthcare Business Today, May 2021
image
GATC Health: Accurate, Personalized, and Predictive Insights into Human Biology

“Initially, the time taken to analyze the multiomic data set of an individual took about 165 hours. Today, the same can be completed in under five minutes and in parallel with millions of datasets due to GATC Health’s ability to process data increasing exponentially over the years.”

- Precison Medicine, October 2021
 

Offering Completed

Competitors

As Genomics/AI companies continue to fetch huge valuations, GATC Health is uniquely positioned to flourish in these new economies. Our proprietary MAT AI/genomics platform and Predictive Multiomics database are proven to deliver groundbreaking results across a variety of lucrative applications advancing human health and scientific progress.

GATC Health’s Competitive Advantage

  • MAT AI provides superior biological context to omics data with the faster processing speed and scalability preferred by major industry partners.

  • The opportunity is immense. GATC’s technology can be taught to address nearly any condition, disease or disorder.

  • Our Predictive Multiomics database and MAT AI make us a complementary technology to others in this space. Companies that may have been competitors can now utilize our technology as partners.
Biological Context
Faster Processing Speed
Scalability

Participate in the Future of Biotech With GATC Health

As the industry continues to push for expedited solutions for Emergency Use Authorizations, drug discovery, biomarker discovery, precision medicine, and more, GATC Health will continue to lead and innovate.

 

It’s an exciting time to be in biotech.

As a GATC Health investor, you’re in the perfect place at the perfect time. Will you step into the future with us?

Offering Completed

Advisory Board

 
image
Dr. Stanley Lewis
Technology Advisor

› Co-Founder and CEO A28 Therapeutics

› 20+ year biotechnology executive. Dr Lewis is the former CMO at TaiMed Biologics (public), Ansun Biopharma (private). Diabetes Relief (private) and Dir. of Drug Development at Tanox (sold to Genentech)

› Developed TROGARZO(TM) from Phase 1 to FDA approval

 
image
Dr. Jack Lewin
Technology Advisor

› Principal and Founder Lewin and Associates LLC

› Chairman, National Coalition on Health Care, Washington DC

› Former President and CEO of Cardiovascular Research Foundation

 
image
Dr. Jonathan Lakey
Science Advisor

› Professor Emeritus, Surgery and Biomedical Engineering

› University of California Irvine

 
image
Mark Palaima
Technology Advisor

› eBay—Chief Architect, Fellow—10 yrs.

› Inkiru, Inc (Acquired by Walmart Labs)—Chief Scientist, Founder

› Ismintis Systems —Founder

 
image
Patrick Lilley
Science Advisor

› CEO and Founder, Liquid Biosciences

› Inventor of over 75 trade secrets and patents

› Co-Chair Blockchain and AI Task Force

› Board Member, Mamogen, HepGene, LiquidLung

 
image
Dr. Chad Beyer
Science Advisor

› PhD, MBA, 25 years of CNS drug discovery and development experience

› 33 INDs; 70+ manuscripts; 2 blockbuster medications

› NIDA; Wyeth; Ariel and Promentis Pharmaceuticals

› Entrepreneur in Residence, Lafayette College

 
image
Dr. Chitra Bhakta
Science Advisor

› Chronic disease specialist

› Physician at OC Integrative Medical Center

 
image
Dr. Negar Motoyagheni
Science Advisor

› Anesthesiology and Intensive Care TUMS/SBU, Scientist UCLA

› Regenerative Medicine Fellowship WFIRM

› 20+ academic certificates

 
image
Dr. David Kushner
Science Advisor

› 35+ years as Nuclear Radiology Specialist / US Navy Physician

› Fellow in Musculoskeletal imaging and Nuclear Medicine

› Assistant professor at Uniform University of the Health Science

Business Advisors

 
image
Steve Lebedoff
Business Advisory Board Member

› President, BeneTrax, an Aon company (Global Risk and Benefit Consulting)

› Strategic Director, National Accounts (Fortune 500) Aon Worksite Solutions

› Executive Officer, PPN Health Access

› Co-founder, Center for Sustainable Healthcare, University of Nevada

 
image
Jim Arellano
Business Advisory Board Member

› President and Founder BP Insurance

› Former VP of National Accounts, United Health Group

› 35+ years’ experience in Healthcare Industry

 
image
Darius Naigamwalla
Business Advisory Board Member

› Executive Vice President, Two Labs Pharmaceutical

› Former CEO, CEEK Enterprises: BioPharma Consulting

› Former President, Campbell Alliance (now Syneos Health)

› 20+ years in BioPharma consulting & commercialization

 
image
LTC (R) Wade Jost
Military + Federal Advisor

› CEO, 640 Areas (Service-Disabled Veteran Owned Small Business

› U.S Army’s Rapid Equipping Forces (REF)

› Office of Secretary of Defense Joint IED Defeat organization

› U.S Military Academy of West Point

 

Offering Completed

Copyright © 2022 · GATC Health

Gatchealth

Gatch Health

Getc health

Gathealth

Get health

Updates

October 03
Lieutenant Colonel (Retired) Wade Jost Joins the Advisory Board of GATC Health Corp

GATC Health, a technology company using advanced multiomic analysis and disruptive artificial intelligence to revolutionize disease detection and drug development, today announced that Lieutenant Colonel (Retired) Wade Jost has joined the company’s board of advisors. LTC (R) Jost brings 35 years of experience in introducing and implementing new products and ideas to the United States Armed Forces. As a leader in process improvement, human capital and change management resulting from both rapid acquisition concepts and normal operating procedures, LTC (R) Jost will be instrumental in introducing GATC Health’s products into the branches of the U.S. Military, including Veterans Affairs.

LTC (R) Jost has extensive experience with various federal agencies requiring deep understanding of critical business drivers in multiple markets and industries. He successfully built relationships with upperlevel decision makers, seizing control of critical problem areas, and delivering on customer commitments. LTC (R) Jost’s experience with synchronizing initiatives affecting DoD’s quick response capability for urgent non-standard needs has enabled him to develop a unique perspective on rapid acquisition concepts, providing oversight in the negotiation and administration of various Federal contracts.

“Wade Jost’s deep knowledge in U.S. military acquisition and logistics opens up new opportunities for our products,” noted Jeff Moses, President of GATC Health. “His passion for leveraging our technology and data to enhance the health of our active and retired armed forces is contagious.”

In partnership with warfighters worldwide, LTC (R) Jost identified emerging capability gaps; oversaw development of solutions within a timeframe relevant to current operations; and facilitated sharing of information with stakeholders to inform and accelerate the deliberate capability development and acquisition processes. He has engaged at senior executive levels throughout the U.S. Federal Government to enable inter-agency collaboration in planning, coordinating, and employing of capabilities. He is currently CEO of 640 Acres, LLC, a certified Service-Disabled Veteran-Owned Small Business (SDVOSB) that provides technology enabled support services to the federal government and commercial customers.

“I am honored to work with GATC Health’s team to identify DoD and VA opportunities that benefit our active-duty personnel and Veterans,” said LTC (R) Jost. “The GATC technology provide a predictive capability for the military chain-of-command that will help maximize their abilities to minimize the adverse effects of a variety of potential medical issues our warfighters face on a daily basis.”

Lieutenant Colonel (Retired) Wade Jost is recognized as a leader for the introduction of rapid acquisition and operational energy organizational structure efforts that has since been emulated by numerous Federal Agencies. He founded and operated two successful Service-Disabled Veteran Owned Small Businesses (SDVOSB) supporting various Federal agencies. He was instrumental in the early development of both the Army’s Rapid Equipping Force’s (REF) acquisition of war time requirements, as well as the Office of the Secretary of Defense’s (OSD) Joint IED Defeat Organization (JIEDDO) technology evaluation and integration efforts simultaneously, a combined effort of over 100 personnel with an annual operating budget in excess of $1B. LTC (R) Jost engaged at highest executive levels in Federal Government to enable inter-agency collaboration in planning, coordinating, and employing of counter-improvised explosive devices (C-IED) products, tactics, techniques, and procedures and help develop the Rapid Acquisition Resourcing Strategy used by Army, OSD, and Congress to defend in the Government War On Terror (GWOT) efforts.

 

Disclaimer The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.

September 28
Dr. Stanley Lewis Joins the Scientific Advisory Board of GATC Health Corp

GATC Health, an innovative technology company focused on whole genome testing and Predictive Multiomics™, today announced that Dr. Stanley Lewis, has joined the company’s board of scientific advisors. With executive management experience in biotechnology, drug development and clinical trials, Dr. Lewis brings 25 years of leadership in biotechnology and a deep understanding of pharmaceutical companies’ target identification and drug design requirements, including designing and conducting Phase 1- 4 clinical trials. Dr. Lewis is committed to innovation and led a clinical development program through FDA approval of the first, host-directed, biologic antiretroviral. In addition to drug development, Dr. Lewis has also practiced internal medicine in both public and private settings. Dr. Lewis will be a key contributor to GATC Health’s product design, regulatory approval processes, and business development. Dr. Lewis’ broad experience in product development will also help guide GATC Health’s business development and marketing teams to capitalize on commercial opportunities.

“Dr. Lewis’ executive management experience with pharmaceutical companies is an asset to our scientific advisory board. His understanding of the needs of drug developers, physicians and consumers will be key in developing our product strategy,” noted Dr. Jonathon Lakey, Chairman of GATC Health’s Scientific Advisory Board. “His passion for enhancing physician-to-patient outcomes through better data supports GATC Health’s vision of developing safer, more efficacious treatments through advanced AI-based technologies.”

Stanley Lewis, MD, MPH is a Founder and the CEO of A28 Therapeutics. a company specializing in development of lytic protein technology for treatment of cancer. Dr. Lewis is also Founder of Eselle Health, Inc., a company developing technology to treat complications of diabetes and other metabolic disorders. Previously, Dr. Lewis held the position of Chief Medical Officer at Ansun Biopharma, TaiMed Biologics, Diabetes Relief, and the St. Hope Foundation. Dr. Lewis was also the Director of Drug Development at Tanox and Medical Director with Genentech Inc./Tanox Prior to his career in biotechnology, Dr. Lewis was Assistant Professor of Medicine in the Department of Internal Medicine at the McGovern Medical School, University of Texas Health Science Center, Houston Texas.

“I am excited to work with GATC’s team to identify and provide actionable data that benefits both patients and providers of care,” said Dr. Lewis. “The GATC technology is perfectly aligned to provide the kind of relevant reports that give physicians and caregivers the information they need to optimize care plans.

 

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.

 

September 17
Dr. Jack Lewin Joins the Scientific Advisory Board of GATC Health Corp

GATC Health, an innovative technology company focused on whole genome testing and Predictive Multiomics™, today announced that Dr. Jack Lewin, has joined the company’s board of scientific advisors. As a well-respected expert in healthcare policy, innovation, business development and research, Dr. Lewin will be a key contributor to GATC Health’s advisory team, especially regarding strategy, policy, and regulatory matters.

Dr. Lewin serves as Chairman of the DC-based National Coalition on Health Care (NCHC), the oldest and largest health policy organization in Washington which advises Congress, the Administration, and the health sector on current health policy and innovation. NCHC’s members include AARP, AFL-CIO, CalPERS and other business and professional coalitions and associations representing over 150 million Americans. Dr. Lewin also serves on the U.S. Food & Drug Administration’s COVID PREPT Task Force, and on various scientific advisory boards. He has advised two U.S. Presidents and was named as one of Modern Healthcare's “100 Most Influential People in Healthcare.”

“It is a tremendous honor to welcome Dr. Lewin to our scientific advisory board. As a nationally recognized leader in healthcare policy, we expect his efforts to be an integral driver of the company’s growth and impact on health,” noted Dr. Jonathan Lakey, Chairman of GATC Health’s Scientific Advisory Board. “His support of our mission is a testament to GATC Health’s pursuit of earlier, more accurate disease detection and faster development of safer, more efficacious treatments through advanced AI-based technologies.”

John C. (Jack) Lewin, MD was President and Chief Executive Officer of the Cardiovascular Research Foundation (CRF), CEO of the American College of Cardiology (ACC), CEO of the California Medical Association (CMA), Hawaii's Director of Health and, as a Commissioned Officer in the United States Public Health Service, was the founder and first Director of the Navajo Nation Department of Health. Dr. Lewin is a recipient of the AMA’s Nathan Davis Award, the American Hospital Association’s Justin Ford Kimball Award, and USPHS Commissioned Officer Association’s Health Leader of the Year award. He received his BA in Biological Sciences from the University of California, Irvine, and his MD and medical training at the University of Southern California. Dr. Lewin has run more than 20 marathons and is an active personal promoter of health, wellness, and disease prevention.

“I am excited to work with GATC’s passionate and extremely experienced team,” said Dr. Lewin. “Their mission to find earlier detection, prevention and treatment across the disease spectrum is backed by their talent and technology.”

 

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.

August 18
GATC Health Welcomes Senior Employee Benefits and Healthcare Leaders to Advisory Team

GATC’s Health Risk Management Platform is a suite of DNAbased early diagnostic tools that provide significant benefits to employees and employers. Armed with personalized health and wellness assessments, employees are empowered to actively participate in the management of their care. Employers can use these tools to help mitigate billions spent annually on employee healthcare and lost productivity. Leading the implementation of the Platform will be new advisory board members Steve Lebedoff, Jim Arelleno, and Wesley Kikuchi.

 

About Steve Lebedoff

Steve Lebedoff has over 30 years of experience as an entrepreneur, innovator, and proven national practice leader in the employee benefits and healthcare arena. He was the founder and President of BeneTrax, an employee benefit data management, communications and human capital analysis technology company. Aon Corporation acquired BeneTrax, and Steve remained on as President helping co-develop Aon Worksite Solutions, where he served on their executive team as Strategic Director of National Accounts. Steve served as a liaison to Aon’s U.S. and Canadian operations, where he worked closely with Aon Risk and Consulting to facilitate worksite solutions and BeneTrax as part of their value proposition to the Fortune 1000 existing and prospective clients. Steve also helped develop strategic partnerships, which included leading state and national trade associations, regional brokers/consultants, financial institutions and national payroll and HR services. Steve participated on various advisory panels and industry practice councils with Aon Risk and Aon Consulting Leadership. Steve also served as an executive officer of PPN Health Access, which was initiated as part of a HRSA grant to support patient/employee healthcare advocacy in Nevada. Steve also cofounded the Center for Sustainable Healthcare, at the University of Nevada, School of Medicine. The Center for Sustainable Healthcare convenes strategic healthcare and technology thought leadership to help accelerate healthcare innovation, research, and grants in support of underserved healthcare populations in Nevada. Steve served as a Governor appointee to the Nevada Healthcare and Medical Services Sector Council. He is a Certified Employee Benefit Specialist through Wharton School, University of Pennsylvania and the International Foundation of Employee Benefit Plans.

 

About Jim Arelleno

Jim Arellano is an accomplished executive and healthcare entrepreneur with over 35 years of industry experience. Mr. Arellano was the Western Region President and Vice President National Accounts for United Health Group. Previously, Jim was the Regional Manager for Blue Shield of California, and the National Accounts Sales Manager for Health Plan of America. Jim Arellano also founded BP Insurance, an employee benefit and risk management brokerage firm that he launched in 1987. BP Insurance generated over $42M in annual premiums and was acquired by Wells Fargo Insurance in 2000. Currently, Jim Arellano is the President and cofounder of PPN Health. PPN Health is a consulting firm focused on helping digital healthcare start-up companies with all aspects of the employer and health plan market business development cycle. This would include market analysis, partner identification, business model development, and deal execution. The PPN Health client base includes Extend Health, which secured over $68M in annual recurring revenue with key clients such as the State of Nevada, Alameda County of California, and Ingersoll Rand. Other PPN Health clients have included MD Live, Cylance and LifeLock - all three companies proceeded later with IPOs or acquisitions by major corporations. Mr. Arellano has served on private and public sector advisory boards including Health Net, Anthem Blue Cross, Guardian Life Insurance, the State of California, and the State of Nevada.

 

About Wesley Kikuchi

Wesley Kikuchi is a successful business development executive who has held roles in executive management, operations, sales, marketing, and engineering. He has a proven track record implementing the necessary strategies to accomplish breakthrough sales objectives while creating market-entry strategies for new business development. Mr. Kikuchi cofounded several live streaming app companies with proprietary SaaS, PaaS and AI. “We are very excited about our new roles and duties in advancing GATC’s commitment to the employer and payer markets. GATC’s Health Risk Management Platform, based on their groundbreaking artificial intelligence engines, will be a game changer for employer health risk management and employee wellness,” Said Steve Lebedoff, Jim Arellano and Wesley Kikuchi in a joint statement.

 

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.

August 01
GATC Health Announces Tyrone Lam as Chief Operating Officer

GATC Health, a science and technology company focused on whole genome analysis and Predictive Multiomics™, today announced that Tyrone Lam was appointed Chief Operating Officer after having served as Business Advisor for the company.  Mr. Lam brings executive management experience in building health technology companies and is responsible for preparing the company for rapid expansion.

Lam brings 30 years of operations, marketing and business development experience in fast-growing technology companies from start-up, venture-backed and public companies. His responsibilities include aligning GATC Health’s operations to capitalize on the company’s advanced AI platform to accelerate and optimize therapeutic discovery and development.

V. Tyrone Lam is co-founder and former COO of First Americans Health & Wellness, bringing specialized treatments and services directly to Native American reservations. Lam served as VP Business Development for Predilytics, an early predictive AI platform for health plans. Lam co-founded OneHealth Solutions (formally OneRecovery), an award-winning pioneer in online behavioral health for individuals, providers and health plans. Lam was president & COO of NTN Buzztime, a publicly traded entertainment technology company. He is also a board-certified life coach focused on personal development.

“Ty’s experience and passion in bringing innovative health technology to the market is a perfect fit for GATC Health,” said John Stroh, interim CEO of GATC Health. “His operational leadership and proven ability to capitalize on new business opportunities aligns with the strong demand for better solutions to accelerate better drug discovery.”

“GATC Health has invented a platform that leapfrogs others in this space to transform the way disease targets are discovered and better drugs are developed,” said Lam. “Our advanced AI platform will close the AI gap to accelerate the world’s transition to personalized medicine.”

 

Disclaimer
The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities.  This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information.  The Company reserves the right to modify or amend the information contained herein.

May 12
GATC Health’s AI-aided Genomics Recognized as High Value Booster for Medicine By HealthCare Business Today

The value of GATC Health’s AI-powered approach to genomics continues to gain attention as a solution for rapid drug discovery and highly accurate diagnostic tools. The latest article in Healthcare Business Today cites the company’s Multiomics Advanced Technology™ (MAT) as the driver for more accurate predictions about disease states and individual responses to diseases and treatments that will make medicine truly personalized.

The company focuses on Predictive Multiomics™, which analyzes the various biological components of an individual to predictively model what may happen when a disease or treatment is involved. GATC’s MAT differs from other systems that use mathematical, algorithm-based models in that it thinks like human biology, mimicking the interdependence of biological systems to deliver more accurate predictions. Because the platform thinks biologically, its use leads to faster and more accurate detection and the identification of more treatment and intervention options.

GATC Health and its partners are currently investigating the causes and treatments for addiction, identifying in just three weeks three new molecules that could form the basis for a new type of addiction treatment. The company believes that in this case, it has accelerated the drug discovery process by approximately 20 percent.

In addition to its work as a valued partner to pharmaceutical companies, GATC Health has created consumer-based platforms to address a number pressing health. So far, GATC has launched platforms for viral immunity, health and wellness, depression and anxiety, and recently announced its new diabetes platform. To read more, visit www.gatchealth.com.

 

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.

Comments

Post comment

Offering Circular

Please read the Offering Circular here: Get Offering Circular

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

THE COMPANY IS “TESTING THE WATERS” UNDER REGULATION A UNDER THE SECURITIES ACT OF 1933. THIS PROCESS ALLOWS COMPANIES TO DETERMINE WHETHER THERE MAY BE INTEREST IN AN EVENTUAL OFFERING OF ITS SECURITIES. THE COMPANY IS NOT UNDER ANY OBLIGATION TO MAKE AN OFFERING UNDER REGULATION A. IT MAY CHOOSE TO MAKE AN OFFERING TO SOME, BUT NOT ALL, OF THE PEOPLE WHO INDICATE AN INTEREST IN INVESTING, AND THAT OFFERING MIGHT NOT BE MADE UNDER REGULATION A. IF THE COMPANY DOES GO AHEAD WITH AN OFFERING, IT WILL ONLY BE ABLE TO MAKE SALES AFTER IT HAS FILED AN OFFERING STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION (SEC) AND THE SEC HAS “QUALIFIED” THE OFFERING STATEMENT. THE INFORMATION IN THAT OFFERING STATEMENT WILL BE MORE COMPLETE THAN THE INFORMATION THE COMPANY IS PROVIDING NOW, AND COULD DIFFER IN IMPORTANT WAYS. YOU MUST READ THE DOCUMENTS FILED WITH THE SEC BEFORE INVESTING.